JP2023500032A5 - - Google Patents

Info

Publication number
JP2023500032A5
JP2023500032A5 JP2022521146A JP2022521146A JP2023500032A5 JP 2023500032 A5 JP2023500032 A5 JP 2023500032A5 JP 2022521146 A JP2022521146 A JP 2022521146A JP 2022521146 A JP2022521146 A JP 2022521146A JP 2023500032 A5 JP2023500032 A5 JP 2023500032A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glp
composition according
receptor agonist
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500032A (ja
JP7670698B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/081087 external-priority patent/WO2021089678A1/en
Publication of JP2023500032A publication Critical patent/JP2023500032A/ja
Publication of JP2023500032A5 publication Critical patent/JP2023500032A5/ja
Priority to JP2024211204A priority Critical patent/JP2025027130A/ja
Application granted granted Critical
Publication of JP7670698B2 publication Critical patent/JP7670698B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521146A 2019-11-06 2020-11-05 認知症におけるglp-1受容体作動薬 Active JP7670698B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024211204A JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるglp-1受容体作動薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19207501.8 2019-11-06
EP19207501 2019-11-06
EP20186623 2020-07-20
EP20186623.3 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024211204A Division JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるglp-1受容体作動薬

Publications (3)

Publication Number Publication Date
JP2023500032A JP2023500032A (ja) 2023-01-04
JP2023500032A5 true JP2023500032A5 (cg-RX-API-DMAC7.html) 2023-11-14
JP7670698B2 JP7670698B2 (ja) 2025-04-30

Family

ID=73172681

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521146A Active JP7670698B2 (ja) 2019-11-06 2020-11-05 認知症におけるglp-1受容体作動薬
JP2024211204A Pending JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるglp-1受容体作動薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024211204A Pending JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるglp-1受容体作動薬

Country Status (19)

Country Link
US (4) US20220280612A1 (cg-RX-API-DMAC7.html)
EP (2) EP4054620B1 (cg-RX-API-DMAC7.html)
JP (2) JP7670698B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110731A (cg-RX-API-DMAC7.html)
CN (1) CN114728042A (cg-RX-API-DMAC7.html)
AU (1) AU2020377469A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007721A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154744A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984177T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241052T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067514T2 (cg-RX-API-DMAC7.html)
IL (1) IL291876A (cg-RX-API-DMAC7.html)
MA (1) MA57599B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022004779A (cg-RX-API-DMAC7.html)
PH (1) PH12022550842A1 (cg-RX-API-DMAC7.html)
PL (1) PL4054620T3 (cg-RX-API-DMAC7.html)
RS (1) RS65780B1 (cg-RX-API-DMAC7.html)
TW (2) TWI890704B (cg-RX-API-DMAC7.html)
WO (1) WO2021089678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
US20230088005A1 (en) * 2020-01-30 2023-03-23 Eli Lilly And Company Therapeutic uses of dulaglutide
EP4262873A4 (en) * 2020-12-16 2024-12-11 The Chinese University of Hong Kong A method for reversing aging brain functional decline
CN118510545A (zh) 2021-12-02 2024-08-16 哥本哈根大学 用于治疗神经退行性疾病的肽-药物缀合物
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2026096637A1 (en) * 2024-10-30 2026-05-07 Tiziana Life Sciences Plc Glp-1 agonists and foralumab combination therapies
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
US8756102B2 (en) * 2009-11-06 2014-06-17 Edatanetworks Inc. Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
HUE049152T2 (hu) * 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Similar Documents

Publication Publication Date Title
JP2572768B2 (ja) レボドパメチルエステルを有効成分とするパ−キンソン病治療剤
JP6353577B2 (ja) 組み合わせ組成物
ES2830447T3 (es) Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
TWI633887B (zh) 用於預防及/或治療多囊性腎臟病之藥物
HRP20241052T1 (hr) Semaglutid, namijenjen liječenju alzheimerove demencije
JP2009514874A5 (cg-RX-API-DMAC7.html)
JP2024503265A5 (cg-RX-API-DMAC7.html)
EP1750677B1 (en) Oral therapeutic compound delivery system
JP2019531310A (ja) 神経炎症と関連した病態を処置するためのデバイス及び方法
JP2019517542A5 (cg-RX-API-DMAC7.html)
WO2021185265A1 (zh) 口服药物组合物
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
IL265761B1 (en) Oral terlipressin compositions for use in treatment of ascites
JP2020522560A5 (cg-RX-API-DMAC7.html)
JP2019218379A5 (cg-RX-API-DMAC7.html)
ES2604254T3 (es) Combinaciones de flurbiprofeno de liberación controlada y relajante muscular
JP5403935B2 (ja) 経口用の慢性疼痛予防または治療剤
IL272834B1 (en) Compositions of amantadine, their preparation, and methods of use
JP2019507786A5 (cg-RX-API-DMAC7.html)
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
JP2007291070A (ja) 催眠用医薬組成物
JP2019535830A5 (cg-RX-API-DMAC7.html)
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
JP2021530568A5 (cg-RX-API-DMAC7.html)
RU2369393C2 (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна